RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 1.09 | $31.0B | $5.7B |
| 2025 Q4 | 0.85 | $30.3B | $9.4B |
| 2025 Q2 | 0.58 | $15.9B | $4.6B |
| 2024 Q4 | 0.32 | $31.6B | $9.9B |
| 2024 Q2 | 0.98 | $30.8B | $6.2B |
| 2023 Q4 | 0.68 | $30.7B | $5.2B |
| 2023 Q2 | 1.12 | $29.8B | $5.6B |
| 2022 Q4 | 0.61 | $31.0B | $6.1B |